i&i Bio, the newly estabilished investment fund powered by i&i Prague and EIF It is our pleasure to announce the start of operations of i&i Biotech Fund (i&i Bio ) in September 2021. This is a great success of i&i Prague team and it brings a new quality and a unique opportunity for early-phase deep-tech spin-offs in Czechia and rest of the Europe. i&i Bio focuses on unique technologies in the fields of Medtech, Diagnostics and Drug discovery. i&i Bio manages more than 45 million EUR and the fund is prepared to invest an average of 2 million EUR (more than 50 million CZK) in a specific project, but in exceptional cases the amount may grow to as much as 4.5 million EUR for a single project. The fund will be joined by further investors in near future including CUIP , the daughter company of the Charles University in Prague. Further details and press release could be found here ! About i&i Bio i&i Bio is a Luxembourg-based venture capital firm that invests in innovative European Life Sciences companies focused on drug discoveries, medical devices, diagnostics, and digital health. The Fund was created thanks to the cooperation of the biotech incubator i&i Prague and the European Investment Fund (see below). With over €45M under management, i&i Bio plans to invest in about 20 early-stage companies. i&i Bio is led by an experienced team of professionals with backgrounds in private equity, healthcare and venture capital supporting entrepreneurs on their journey to global success. Thanks to the close cooperation with the fund’s sponsor, the biotech academic incubator i&i Prague, i&i Bio is supporting and advancing transformative Central European technology companies. For more information visit www.inibio.eu . About European Investment Fund i&i Bio is supported by an investment from the EIF, with the support of: lnnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing; and the Pan-European Guarantee Fund (EGF), implemented by the EIF with the financial support of the Participating Member States. The objective of EGF is to respond to the economic impact of the COVID-19 pandemic by ensuring that companies in the Participating Member States have sufficient short-term liquidity available to weather the crisis and are able to continue their growth and development in the medium to long-term.

We’ll show you what’s new with us here, offer you interesting media outlets that relate to our work, and you can find our press releases here. Our news We help invention grow! Welcome to the News section of i&i Prague – your go-to source for the latest updates straight from our incubator! This is where we keep you informed about everything happening at i&i Prague. Stay up to date with how we are driving innovation and turning scientific discoveries into real-world solutions. Whether you're a researcher, investor, or entrepreneur, this is the place to discover what’s new at i&i Prague. Highlights Job for you For our projects, we are looking for a Junior Incubation and Market Intelligence Manager. Maybe it's you... Read More Press release i&i Prague, Technical University of Liberec, and the Faculty of Medicine of CU in Pilsen will support the Nanoflexion technology Read More Podcast CHEMAGAZÍNtalks podcast presents Jan Berka: "At one point, we held the unofficial record for the longest DNA reading." Read More Interview "I love the feeling you get when you discover something new," says Kamila Burdová, the new incubation manager at i&i Prague. Read More Blog Our "Swiss Journey" Continues: From CometX at the University of Zurich to the Innovation Biotech Day 2025 in Prague Read More Press release i&i Prague and the Nencki Institute launch collaboration to develop an innovative test for early diagnosis of Alzheimer’s disease Read More Other news Mar 18 2025 Jiří Růžička: The Start-up/Spin-off Gives Scientists the Opportunity to Help Shape the Path of Their Discovery Read More Mar 18 2025 i&i Prague, ÚHKT and Medirekt Partner Join Forces to Bring an Innovative Sample Preparation Technology to Market Read More Feb 25 2025 Czech i&i Prague and the Polish Medical Innovation Institute join forces to support cutting-edge scientific innovation in the region Read More Feb 2 2025 CHEmic podcast with Milan Prasil about how to turn a scientific discovery into a successful start-up/spin-off Read More Jan 20 2025 Neuron 2024 Award for Bridging Science and Business Goes to SophoMer, s.r.o., a Startup from i&i Prague's Portfolio Read More Nov 23 2024 David Stíbal: We believe a startup is one of the best paths nowadays to develop interesting technologies beyond the academic level Read More Nov 7 2024 i&i Prague and other Prague.bio members participate in a business mission with Czech president in Switzerland Read More Oct 30 2024 Jiří Moos: From the lab to the market: What biotech commercialization looks like from the perspective of an incubator Read More Oct 21 2024 PANC-CKI Consortium led by CasInvent Pharma Secures €4M Eurostars Grant for Pancreatic Cancer Research Read More Sep 24 2024 The Prague.bio Conference 2024 welcomed approximately 300 participants from all over the world Read More Mar 11 2024 This fall Prague will be the stage for a showcase of cutting-edge biotechnologies featuring prominent figures such as ... Read More Now 30, 2024 CasInvent Pharma raises € 1.6 million from i&i Prague and Other Investors to Support the Development of CK1 Inhibitors for ... Read More Now 30, 2023 IOCB Tech Group Successfully Represents the Czech Republic at the Prestigious Biotech Conference BIO-Europe 2023 Read More Apr 25, 2023 The Prague.bio international conference will bring together the best of science and business in Prague Read More Feb 7, 2023 New startup in our portfolio: Sophomer's technology will make immunoassays faster, easier and cheaper Read More Feb 6, 2023 Czech liquid biopsy startup Elphogene comes under full control of one of the founders Read More Earlier News

Licensing agreement for a novel SARS Cov-2 virus neutralization antibody test was signed We are very happy to inform you that i&i Prague has participated on a development of novel in vitro diagnostics test measuring virus neutralization antibodies against SARS Cov-2 in human blood. The project was successfully completed and the Institute of Organic Chemistry and Biochemistry (IOCB) and the Institute of Biotechnology (IBT) have signed an exclusive license agreement with the company Immunotech, the Prague based subsidiary of Beckman Coulter. Read more information on IOCB webpage. 12 mouse monoclonal antibody clones against different domains of SARS Cov-2 Spike protein were generated in this project and are available for research or other use. For more information about the new test and the available antibody clones, contact: Dr. Jiří Moos moos@iniprague.com

< Back Alexandr Krajhanzl Board of Directors Alexandr Krajhanzl has been a part of i&i Prague since September 2021. He is also a member of the Board for the Commercialization of Science and Research Results of Charles University Prague. Between 1993 and 2004 he worked in various General Management functions in Cilag, later Janssen-Cilag, Johnson & Johnson. In 2004 as the Regional Director he became responsible for Business Development in EMEA Emerging Markets (80 countries) at Janssen, J&J Pharmaceutical companies. His responsibility changed from 2010 until 2017 when he acted as the Regional Director of New Business Development in the territory covering Europe Mid-Sized Markets. Between 2004 and 2017 he was a member of the Global BD team responsible for L&A and M&A initiatives and projects in Infectious Diseases and Vaccines. During his tenure in this position, he led or participated in numerous global, regional and local L&A and M&A deals. For his contribution, he was rewarded with two Global Standards of Leadership Awards of Johnson & Johnson. Between 2013 and 2019 he also served as the President and Founding Member of Pharma Licensing Group Central and Eastern Europe and Vice-President of the European Pharma Licensing Board. Alexandr completed his Master’s degree in Chemistry at Charles University in Prague. He has received a Ph.D. (CSc.) degree in Biochemistry and worked as a Charles University teacher for almost 11 years at the Department of Biochemistry, Faculty of Science. Should you be interested in a collaboration in the field of drug development, Alexandr will be the right contact whom you can meet. He has been in the world of science and its commercialization for more than 20 years and has an extensive network of contacts among Pharma and Medical Device companies.